• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善精神分裂症患者的功能:阿立哌唑一月一次(REACT 研究)的真实世界疗效。

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).

机构信息

University of Calgary, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada.

Lundbeck Canada Inc, 2600 Alfred-Nobel Boulevard, Saint-Laurent, QC, H4S 0A9, Canada.

出版信息

BMC Psychiatry. 2023 May 31;23(1):383. doi: 10.1186/s12888-023-04893-8.

DOI:10.1186/s12888-023-04893-8
PMID:37259053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10233885/
Abstract

BACKGROUND

Functional impairment affects many patients with schizophrenia. Treatment with the long-acting injectable antipsychotic aripiprazole once-monthly (AOM) may help improve functioning.

OBJECTIVES

To explore changes in functioning in patients with schizophrenia who received AOM treatment in observational studies.

METHODS

Here we report functional outcomes in the form of Global Assessment of Functioning (GAF) scores in a pooled analysis of data from two observational studies from Canada (NCT02131415) and Germany (vfa non-interventional studies registry 15960N). Data from 396 patients were analyzed.

RESULTS

At baseline, the mean GAF score was 47.7 (SD 13.4). During 6 months of treatment with AOM, the mean GAF score increased to 59.4 (SD 15.8). Subgroups stratified by patient age (≤35 years/>35 years), sex, disease duration (≤5 years/>5 years) and disease severity at baseline had all significantly improved their GAF at month 6. 51.5% of the patients showed a GAF score increase of at least 10 points, which was regarded as clinically meaningful, and were considered responders.

CONCLUSIONS

These data show that treatment with AOM may help improve patient functioning in a routine treatment setting.

TRIAL REGISTRATION

NCT02131415 (May 6, 2014), vfa non-interventional studies registry 15960N.

摘要

背景

功能障碍影响许多精神分裂症患者。长效注射用抗精神病药阿立哌唑每月一次(AOM)治疗可能有助于改善功能。

目的

在观察性研究中探讨接受 AOM 治疗的精神分裂症患者功能的变化。

方法

我们在此报告来自加拿大(NCT02131415)和德国(vfa 非干预性研究登记 15960N)两项观察性研究数据的汇总分析中以总体功能评估(GAF)评分形式呈现的功能结果。共分析了 396 例患者的数据。

结果

基线时,平均 GAF 评分为 47.7(SD 13.4)。在接受 AOM 治疗的 6 个月期间,平均 GAF 评分增加到 59.4(SD 15.8)。按患者年龄(≤35 岁/>35 岁)、性别、疾病持续时间(≤5 年/>5 年)和基线疾病严重程度分层的亚组在第 6 个月时均显著改善了 GAF。51.5%的患者 GAF 评分至少增加了 10 分,这被认为具有临床意义,被认为是应答者。

结论

这些数据表明,在常规治疗环境中,AOM 治疗可能有助于改善患者的功能。

试验注册

NCT02131415(2014 年 5 月 6 日),vfa 非干预性研究登记 15960N。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/9c7a12bb6850/12888_2023_4893_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/fd4bc1fd6066/12888_2023_4893_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/ba393dff85e6/12888_2023_4893_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/897c885d0cc4/12888_2023_4893_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/565c45240be5/12888_2023_4893_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/938589248a69/12888_2023_4893_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/9c7a12bb6850/12888_2023_4893_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/fd4bc1fd6066/12888_2023_4893_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/ba393dff85e6/12888_2023_4893_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/897c885d0cc4/12888_2023_4893_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/565c45240be5/12888_2023_4893_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/938589248a69/12888_2023_4893_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c92/10233885/9c7a12bb6850/12888_2023_4893_Fig6_HTML.jpg

相似文献

1
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).改善精神分裂症患者的功能:阿立哌唑一月一次(REACT 研究)的真实世界疗效。
BMC Psychiatry. 2023 May 31;23(1):383. doi: 10.1186/s12888-023-04893-8.
2
BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study).汇总分析利培酮长效针剂与阿立哌唑长效针剂治疗精神分裂症的非干预性研究(REACT 研究)中的 BPRS 各领域、项目和亚组分析以及 CGI-I 评分。
BMC Psychiatry. 2023 Mar 14;23(1):162. doi: 10.1186/s12888-023-04651-w.
3
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.现实生活中评估阿立哌唑每月(安律凡注射用长效混悬剂)治疗精神分裂症的疗效:一项加拿大自然主义非干预性前瞻性队列研究。
BMC Psychiatry. 2019 Apr 16;19(1):114. doi: 10.1186/s12888-019-2103-x.
4
Medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy.通过每月一次使用阿立哌唑减少精神分裂症患者的药物负担并获得早期临床获益。
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Dec 20;135:111115. doi: 10.1016/j.pnpbp.2024.111115. Epub 2024 Aug 6.
5
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies.阿立哌唑一月一次 REACT 真实世界研究的实际效果:两项非干预性研究的汇总分析。
Eur Psychiatry. 2022 Jul 20;65(1):e42. doi: 10.1192/j.eurpsy.2022.27.
6
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.在德国进行的一项多中心、前瞻性、非对照、开放性队列研究中使用长效阿立哌唑:关于功能全面评估和世界卫生组织幸福指数的报告。
BMC Psychiatry. 2020 Feb 22;20(1):77. doi: 10.1186/s12888-020-02488-1.
7
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.奥氮平长效针剂治疗口服奥氮平预处理的精神分裂症患者的有效性:一项 6 个月的真实世界、非干预性研究。
BMC Psychiatry. 2018 Nov 14;18(1):365. doi: 10.1186/s12888-018-1946-x.
8
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.奥氮平起始治疗对精神分裂症患者医疗资源利用和医疗成本的影响:来自美国理赔数据的真实世界证据。
J Med Econ. 2023 Jan-Dec;26(1):316-325. doi: 10.1080/13696998.2023.2178770.
9
Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.在西班牙临床实践中,接受阿立哌唑每月长效注射治疗的精神分裂症患者持续治疗的预测因素:一项回顾性、观察性研究。
Eur Psychiatry. 2021 Apr 12;64(1):e40. doi: 10.1192/j.eurpsy.2021.23.
10
Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.从口服抗精神病药物转换而来的患者中,每月一次阿立哌唑对精神分裂症症状的影响。
CNS Spectr. 2016 Dec;21(6):460-465. doi: 10.1017/S1092852916000365. Epub 2016 Aug 17.

引用本文的文献

1
Quantifying the Tolerability of Antipsychotic Treatment-Related Side Effects in Schizophrenia: A Survey Study of Patients and Caregiver Proxies.量化精神分裂症中抗精神病药物治疗相关副作用的耐受性:一项针对患者及照顾者代理人的调查研究
Patient Prefer Adherence. 2025 Sep 9;19:2821-2834. doi: 10.2147/PPA.S466742. eCollection 2025.
2
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study.长效利培酮治疗精神分裂症的长期疗效:ReLiAM 研究的第 2 年结果。在功能和生活质量方面。
BMC Psychiatry. 2024 Nov 14;24(1):797. doi: 10.1186/s12888-024-06240-x.

本文引用的文献

1
Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies.阿立哌唑一月一次 REACT 真实世界研究的实际效果:两项非干预性研究的汇总分析。
Eur Psychiatry. 2022 Jul 20;65(1):e42. doi: 10.1192/j.eurpsy.2022.27.
2
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.日常实践中不符合随机临床试验条件的精神分裂症患者的特征及结局
JAMA Psychiatry. 2022 Mar 1;79(3):210-218. doi: 10.1001/jamapsychiatry.2021.3990.
3
Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses.
提高对精神分裂症功能结局途径的认识:意大利精神病研究网络的主要结果
Front Psychiatry. 2021 Dec 14;12:791117. doi: 10.3389/fpsyt.2021.791117. eCollection 2021.
4
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.在德国进行的一项多中心、前瞻性、非对照、开放性队列研究中使用长效阿立哌唑:关于功能全面评估和世界卫生组织幸福指数的报告。
BMC Psychiatry. 2020 Feb 22;20(1):77. doi: 10.1186/s12888-020-02488-1.
5
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.现实生活中评估阿立哌唑每月(安律凡注射用长效混悬剂)治疗精神分裂症的疗效:一项加拿大自然主义非干预性前瞻性队列研究。
BMC Psychiatry. 2019 Apr 16;19(1):114. doi: 10.1186/s12888-019-2103-x.
6
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.奥氮平长效针剂治疗口服奥氮平预处理的精神分裂症患者的有效性:一项 6 个月的真实世界、非干预性研究。
BMC Psychiatry. 2018 Nov 14;18(1):365. doi: 10.1186/s12888-018-1946-x.
7
Rehabilitation Interventions to Promote Recovery from Schizophrenia: A Systematic Review.促进精神分裂症康复的康复干预措施:一项系统综述。
Front Psychiatry. 2017 Jun 12;8:100. doi: 10.3389/fpsyt.2017.00100. eCollection 2017.
8
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.长效注射用抗精神病药在精神分裂症中的应用:评估证据。
J Clin Psychiatry. 2016;77(suppl 3):1-24. doi: 10.4088/JCP.15032su1.
9
Issues and developments related to assessing function in serious mental illness.与严重精神疾病功能评估相关的问题与进展
Dialogues Clin Neurosci. 2016 Jun;18(2):135-44. doi: 10.31887/DCNS.2016.18.2/dvelligan.
10
Minimum Clinically Important Difference in the Global Assessment Functioning in Patients with Schizophrenia.精神分裂症患者全球功能评估中的最小临床重要差异
Value Health. 2014 Nov;17(7):A765-6. doi: 10.1016/j.jval.2014.08.285. Epub 2014 Oct 26.